Three verifiable, current price targets from named firms form the basis of this analysis. H.C. Wainwright initiated coverage with a Buy rating and a $28 target in August 2026 and maintained that view in November 2026. Leerink Partners, whose analyst David Risinger lowered the target to $24 from $30 in May 2026, keeps an Outperform rating. In sharp contrast, Wedbush holds an Underperform rating with a $2 target, reflecting a fundamentally different read on the company's prospects.
The simple average of these three targets is $18.00, which is the central target used here. It is important to stress that this is a calculated arithmetic mean of attributed targets, not an official published consensus, and the $2-to-$28 range shows how little agreement exists. The bullish cases lean on IMG-007's addressable market and clinical progress, while the cautious view weighs execution risk and capital needs. I also checked this using Tickeron’s AI Screener to see how IMA compares to others in the industry.
With the stock near $3.92 as of late November 2026, moving to $18 implies upside of roughly 359%. That qualifies as a very large move by any standard measure and would require a sustained re-rating of the company, not merely a modest data beat. The path would most plausibly run through positive Phase 2 or later-stage results for IMG-007, successful advancement toward pivotal trials, and a materially improved funding position. None of these outcomes is assured, and no timing should be assumed.
The central bull argument is IMG-007's potential in atopic dermatitis and alopecia areata, indications with large patient populations and significant unmet need. Positive Phase 2a data already generated in both conditions form the foundation of the bullish targets. If the program demonstrates differentiated efficacy and safety against established and emerging therapies, the stock could attract renewed institutional interest and higher valuations. Additional supportive factors would include a strengthened balance sheet, favorable capital markets for biotech, and analyst upgrades or target increases.
The principal obstacle is that ImageneBio remains a clinical-stage company with no approved products and recurring net losses, reporting a GAAP net loss of roughly $10 million in the quarter ended June 30, 2026. Like many early biotechs, it depends on further financing, which can dilute existing shareholders and pressure the share price. Any disappointing data, regulatory setbacks, or slower-than-expected trial enrollment could sharply reduce the probability of reaching $18. Broader sector conditions, including risk appetite for speculative biotech and interest-rate trends, also matter. Wedbush's $2 target illustrates that the downside scenario is a meaningful part of the analyst debate.
As a low-priced, thinly traded micro-cap, ImageneBio offers limited durable technical structure. The stock trades well below its post-merger highs and has experienced substantial volatility since the 2025 combination. The analyst range itself — $2 on the low end and $28 on the high end — frames the practical extremes of market expectation. Psychological whole-dollar levels and any catalyst-driven volume surges are more relevant here than long-established support or resistance zones. From what I see, this volatility makes monitoring tools especially useful.
Analyst price targets typically reflect a research horizon of about 12 months, though firms do not always publish a precise period. Investors should monitor IMG-007 clinical updates and data readouts, quarterly earnings and cash-burn disclosures, any financing or dilution events, and analyst rating or target revisions. Sector-level shifts in biotech sentiment and interest-rate expectations can also influence how aggressively the market prices clinical-stage companies. I’m watching this closely as new data emerges.
In my own research process, I rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of names like IMA. These signals apply artificial intelligence to monitor thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold recommendations based on technical behavior and market shifts. Pairing them with fundamental work on clinical progress and analyst views helps add context without replacing careful due diligence.
Can ImageneBio reach $18? The target reflects the arithmetic mean of three widely divergent analyst views, not a forecast of certainty. From a recent price near $3.92, the required move of about 359% is very large and would depend on successful clinical execution and a re-rating of the company's prospects. The bullish $28 and $24 targets rest on IMG-007's potential in large inflammatory disease markets, while Wedbush's $2 target underscores genuine execution and financing risk. Investors should weigh both scenarios and monitor upcoming clinical data and capital developments rather than treating the $18 figure as a probable outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The RSI Oscillator for IMA moved out of oversold territory on November 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 32 of the 36 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where IMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for IMA just turned positive on November 19, 2026. Looking at past instances where IMA's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMA advanced for three days, in 172 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMA as a result. In 95 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMA entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.331) is normal, around the industry mean (3.596). P/E Ratio (-0.876) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (35.971) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. IMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology